SCHEMBL13610889

SCHEMBL13610889

NC[C@@H]1CCN(Cc2ccccc2)CC1O

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 2/20 0.57
ALDH1A1 P00352 1/20 0.55
SLC18A3 Q16572 1/20 0.54
GBA1 P04062 1/20 0.52
ACHE P22303 2/20 0.49
BCHE P06276 1/20 0.49
BACE1 P56817 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
CCR3 P51677 1/20 0.47
GRIN1 Q05586 1/20 0.47
GRIN2B Q13224 1/20 0.47
SIGMAR1 Q99720 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707425 1.00 FUCA1 (0.57) FUCA1ALDH1A1SLC18A3GBA1ACHE
SCHEMBL3547837 0.88 ALDH1A1 (0.55) FUCA1ALDH1A1SLC18A3GBA1ACHE
SCHEMBL3547834 0.88 ALDH1A1 (0.55) FUCA1ALDH1A1SLC18A3GBA1ACHE
SCHEMBL3547840 0.88 ALDH1A1 (0.55) FUCA1ALDH1A1SLC18A3GBA1ACHE
SCHEMBL5999878 0.86 FUCA1 (0.58) FUCA1ALDH1A1SLC18A3GBA1ACHE
SCHEMBL1315585 0.86 GBA1 (0.66) FUCA1ALDH1A1SLC18A3GBA1ACHE
SCHEMBL5999883 0.86 FUCA1 (0.58) FUCA1ALDH1A1SLC18A3GBA1ACHE
SCHEMBL505547 0.86 GBA1 (0.66) FUCA1ALDH1A1SLC18A3GBA1ACHE
SCHEMBL1315584 0.86 GBA1 (0.66) FUCA1ALDH1A1SLC18A3GBA1ACHE
SCHEMBL458459 0.86 GBA1 (0.66) FUCA1ALDH1A1SLC18A3GBA1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638535-B2 (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-29 US disclosed